BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 20, 2020
View Archived Issues
How hook(worm)s grapple with nets
Read More
Heat-shock proteins' subtler cousin
Read More
GLP1R agonist-DYRK1A inhibitor combination enhances beta cell proliferation with better specificity
Read More
AGAP2-AS1 as a new biomarker to identify low-risk progressors in ccRCC
Read More
Immunotherapy with pembrolizumab plus HER2 BATs shows promise in mCRPC
Read More
Dose-escalation data presented from phase Ib/II study of cetrelimab plus erdafitinib in mUC
Read More
First patient enrolled in phase II study of PL-9643 for the treatment of dry eye
Read More
Terns Pharmaceuticals completes phase I study of TERN-101
Read More
First subject dosed in phase I study of TAK-169 in multiple myeloma
Read More
resTORbio presents interim phase Ib/IIa data for RTB-101 in PD along with corporate update
Read More
Mitsubishi Tanabe Pharma describes new autotaxin inhibitors
Read More
APOBEC3B predicts good prognosis with gemcitabine plus platinum therapy in patients with mUC
Read More
Mutabilis discovers bacterial beta-lactamase inhibitors
Read More
New HDAC inhibitors disclosed by Merck & Co.
Read More
Lilly identifies new O-GlcNAcase inhibitors
Read More
STING agonists patented by Incyte
Read More
Progress in Human Cell Atlas unveiling underlying mechanisms of disease
Read More
TUBB3 predicts prognosis in patients with metastatic prostate cancer under abiraterone therapy
Read More
GeneTX recruits pediatric patients with Angelman syndrome for phase I/II study of GTX-102
Read More
Immutep reports interim data from phase II study of eftilagimod alpha in NSCLC and HNSCC
Read More
New phase I trial evaluates safety and immunogenicity of dengusiil
Read More
[68Ga]PSMA-11 PET/CT has a large effect on prostate cancer staging and management
Read More